Previous 10 | Next 10 |
Aurinia Pharmaceuticals ( NASDAQ: AUPH ) has reported prelim net revenue of ~$28.4M for fourth quarter compared to consensus estimate of $27.13M. For the three months ended Dec. 31, 2022, preliminary unaudited net revenues included net product revenues of ~$28.3M and license a...
Preliminary unaudited net revenue for the fourth quarter and full year 2022 of approximately $28.4 million and $134.0 million Preliminary unaudited net product revenue for the fourth quarter and full year 2022 of approximately $28.3 million and $103.5 million Reiterates net produc...
Summary Aurinia Pharmaceuticals Inc. recently settled a patent dispute with Sun Pharma. That seems to have rekindled buyout chatter. However, without an actual buy - which is an unpredictable event - Aurinia Pharmaceuticals has no upside, given poor voclosporin sales. In m...
Summary Aurinia Pharmaceuticals recently announced they have reached a settlement with Sun Pharmaceuticals concerning the patent challenge for Lupkynis. Both companies will dismiss their claims and counterclaims against each other. Following the settlement announcement, AUPH shares jump...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11 th at 4:30 p.m. Pacific Time / 7:30 p.m....
Aurinia Pharmaceuticals ( NASDAQ: AUPH ) rose 5% amid speculation the company may be a takeover target after Tuesday's patent settlement with Sun Pharmaceuticals. Aurinia ( AUPH ) surged 38% on Tuesday after the company said it reached a settlement with India's Sun Pharmac...
Canada-based Aurinia Pharmaceuticals ( NASDAQ: AUPH ) on Tuesday said it had reached a settlement with India's Sun Pharmaceuticals ( OTCPK:SMPQY ) over its patent challenge of its lupus nephritis treatment Lupkynis. AUPH shares were 36.1% higher to $5.88 after the opening bell...
- Sun Pharmaceuticals and Aurinia agreed to file a joint motion to dismiss Inter Parties Review of Patent No. 10,286,036 - Parties have settled the patent infringement claim against Sun’s CEQUA® product - Settlements are Contingent Upon U.S. Patent Trial and Appeal Board (PTAB...
MHRA Approval follows European Commission marketing authorization of LUPKYNIS to treat adults with active lupus nephritis in 27 European Union Member States LUPKYNIS is the first oral medicine approved in the U.S. and Europe for the treatment of adults living with active lupus nephritis ...
Summary Aurinia has been facing many problems. Potential sales chatter may be a result of its problems. However, I see little reason for big pharma to buy AUPH. Aurinia’s ( AUPH ) price movement over the last 12 months seems predicated on 3 things - key ma...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...